# Kangpu Biological Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangpu-biological-medicine

- Industry: Pharmaceuticals
- Headquarters: Hefei, China
- Website: www.kangpugroup.com
- Total disclosed funding: $53M
- Latest round: Series B (Aug 30, 2023)
- Investors on record: 9

## About

Established in 2011 and based in Shanghai, China, Kangpu Biological Medicine is a medical company that focuses on the development of innovative small molecule targeted immunomodulatory drugs. In 2014, the company screened out the compound KPG-121. In 2017, it received U.S. FDA clinical approval for KPG-121 for the treatment of advanced prostate cancer. Dr. Chuangsheng Ge, the company's co-founder, chairman and CEO, worked in Novartis, Celgene and Schering-Plough. In August 2023, Kangpu Biological Medicine raised approximately CNY 100 million in series B+ funding.

The company engages in the development of innovative small molecule targeted immunomodulatory drugs. The company has established multiple R&D pipelines in the field of diseases such as prostate cancer, myelodysplastic syndrome and diffuse large B-cell lymphoma, etc. The company's small molecule immunomodulatory targeted drugs utilize the mechanism of protein ubiquitination and degradation. The drugs can be used in curing cancer, autoimmune diseases and inflammation.

## Funding rounds

- Series B, Aug 30, 2023, $14M — NLVC, Yinxinggu Capital, V-Capital, Lapam Capital, Yijing Investment, Realharmony Capital
- Series B, May 10, 2021, $39M — Zhongguancun Venture Capital, E-Town International Industrial Investment, Lapam Capital, Yijing Investment, Realharmony Capital, ABC International Capital
- Series A, Jun 22, 2018 — NLVC

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- Zhongguancun Venture Capital (https://capitalatlas.ai/funds/zhongguancun-venture-capital) — Series B
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- Realharmony Capital (https://capitalatlas.ai/funds/realharmony-capital) — Series B
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series B
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series B